291 related articles for article (PubMed ID: 33339117)
1. Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis.
Visser WCH; de Jong H; Melchers WJG; Mulders PFA; Schalken JA
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33339117
[TBL] [Abstract][Full Text] [Related]
2. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.
Olleik G; Kassouf W; Aprikian A; Hu J; Vanhuyse M; Cury F; Peacock S; Bonnevier E; Palenius E; Dragomir A
J Natl Compr Canc Netw; 2018 Nov; 16(11):1340-1351. PubMed ID: 30442734
[No Abstract] [Full Text] [Related]
4. An overview of biomarkers in the diagnosis and management of prostate cancer.
Uhr A; Glick L; Gomella LG
Can J Urol; 2020 Aug; 27(S3):24-27. PubMed ID: 32875999
[TBL] [Abstract][Full Text] [Related]
5. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in prostate cancer - Current clinical utility and future perspectives.
Kretschmer A; Tilki D
Crit Rev Oncol Hematol; 2017 Dec; 120():180-193. PubMed ID: 29198331
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer biomarkers and multiparametric MRI: is there a role for both in prostate cancer management?
Saltman A; Zegar J; Haj-Hamed M; Verma S; Sidana A
Ther Adv Urol; 2021; 13():1756287221997186. PubMed ID: 33737957
[TBL] [Abstract][Full Text] [Related]
8. Are localized prostate cancer biomarkers useful in the clinical practice?
Carneiro A; Priante Kayano P; Gomes Barbosa ÁR; Langer Wroclawski M; Ko Chen C; Cavlini GC; Reche GJ; Sanchez-Salas R; Tobias-Machado M; Sowalsky AG; Bianco B
Tumour Biol; 2018 Sep; 40(9):1010428318799255. PubMed ID: 30204063
[TBL] [Abstract][Full Text] [Related]
9. A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.
Kohaar I; Petrovics G; Srivastava S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013716
[TBL] [Abstract][Full Text] [Related]
10. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
Hendriks RJ; van der Leest MMG; Dijkstra S; Barentsz JO; Van Criekinge W; Hulsbergen-van de Kaa CA; Schalken JA; Mulders PFA; van Oort IM
Prostate; 2017 Oct; 77(14):1401-1407. PubMed ID: 28853167
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for prostate cancer detection and risk stratification.
Farha MW; Salami SS
Ther Adv Urol; 2022; 14():17562872221103988. PubMed ID: 35719272
[TBL] [Abstract][Full Text] [Related]
12. Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in Diagnosis and Prognosis.
Matuszczak M; Schalken JA; Salagierski M
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282798
[TBL] [Abstract][Full Text] [Related]
13. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men.
Hendriks RJ; van der Leest MMG; Israël B; Hannink G; YantiSetiasti A; Cornel EB; Hulsbergen-van de Kaa CA; Klaver OS; Sedelaar JPM; Van Criekinge W; de Jong H; Mulders PFA; Crawford ED; Veltman J; Schalken JA; Barentsz JO; van Oort IM
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1110-1119. PubMed ID: 33941866
[TBL] [Abstract][Full Text] [Related]
14. The Use of Biomarkers in Prostate Cancer Screening and Treatment.
Alford AV; Brito JM; Yadav KK; Yadav SS; Tewari AK; Renzulli J
Rev Urol; 2017; 19(4):221-234. PubMed ID: 29472826
[TBL] [Abstract][Full Text] [Related]
15. PROPOSe: A Real-life Prospective Study of Proclarix, a Novel Blood-based Test to Support Challenging Biopsy Decision-making in Prostate Cancer.
Steuber T; Heidegger I; Kafka M; Roeder MA; Chun F; Preisser F; Palisaar RJ; Hanske J; Budaeus L; Schiess R; Keller T; Semjonow A; Hammerer P; Manka L; Ecke T; Schwentner C; Ohlmann C
Eur Urol Oncol; 2022 Jun; 5(3):321-327. PubMed ID: 33422560
[TBL] [Abstract][Full Text] [Related]
16. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.
Nicholson A; Mahon J; Boland A; Beale S; Dwan K; Fleeman N; Hockenhull J; Dundar Y
Health Technol Assess; 2015 Oct; 19(87):i-xxxi, 1-191. PubMed ID: 26507078
[TBL] [Abstract][Full Text] [Related]
17. The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy?
Porpiglia F; Russo F; Manfredi M; Mele F; Fiori C; Bollito E; Papotti M; Molineris I; Passera R; Regge D
J Urol; 2014 Jul; 192(1):60-6. PubMed ID: 24518780
[TBL] [Abstract][Full Text] [Related]
18. Clinical Biofluid Assays for Prostate Cancer.
Borbiev T; Kohaar I; Petrovics G
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201592
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds.
Kawada T; Shim SR; Quhal F; Rajwa P; Pradere B; Yanagisawa T; Bekku K; Laukhtina E; von Deimling M; Teoh JY; Karakiewicz PI; Araki M; Shariat SF
Eur Urol Oncol; 2023 Nov; ():. PubMed ID: 37981495
[TBL] [Abstract][Full Text] [Related]
20. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy.
Scattoni V; Lazzeri M; Lughezzani G; De Luca S; Passera R; Bollito E; Randone D; Abdollah F; Capitanio U; Larcher A; Lista G; Gadda GM; Bini V; Montorsi F; Guazzoni G
J Urol; 2013 Aug; 190(2):496-501. PubMed ID: 23466239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
